307 related articles for article (PubMed ID: 24599799)
1. A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
Ooka Y; Chiba T; Ogasawara S; Arai K; Suzuki E; Tawada A; Yamashita T; Kanai F; Kaneko S; Yokosuka O
Invest New Drugs; 2014 Aug; 32(4):723-8. PubMed ID: 24599799
[TBL] [Abstract][Full Text] [Related]
2. Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
Lv Y; Liang R; Hu X; Liu Z; Liao X; Lin Y; Yuan C; Liao S; Li Q; Zhang J; Li Y
Pharmazie; 2014 Oct; 69(10):759-63. PubMed ID: 25985566
[TBL] [Abstract][Full Text] [Related]
3. Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
Cai Z; Wang C; Liu P; Shen P; Han Y; Liu N
Phytomedicine; 2016 Nov; 23(12):1295-1300. PubMed ID: 27765348
[TBL] [Abstract][Full Text] [Related]
4. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
5. S-1 plus sorafenib for the treatment of advanced hepatocellular carcinoma.
Huang W; You L; Liu D; Yang S; Liu M; Wang H; Wang P; Baikere P; Gu P; Abulikemu A; Yuan S; Fan X
J BUON; 2016; 21(6):1388-1393. PubMed ID: 28039697
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Lee SJ; Lee J; Park SH; Park JO; Park YS; Kang WK; Lee J; Yim DS; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1540-7. PubMed ID: 21695438
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).
Hubbard JM; Mahoney MR; Loui WS; Roberts LR; Smyrk TC; Gatalica Z; Borad M; Kumar S; Alberts SR
Target Oncol; 2017 Apr; 12(2):201-209. PubMed ID: 27943153
[TBL] [Abstract][Full Text] [Related]
8. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Kelley RK; Nimeiri HS; Munster PN; Vergo MT; Huang Y; Li CM; Hwang J; Mulcahy MF; Yeh BM; Kuhn P; Luttgen MS; Grabowsky JA; Stucky-Marshall L; Korn WM; Ko AH; Bergsland EK; Benson AB; Venook AP
Ann Oncol; 2013 Jul; 24(7):1900-1907. PubMed ID: 23519998
[TBL] [Abstract][Full Text] [Related]
9. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.
Sho T; Nakanishi M; Morikawa K; Ohara M; Kawagishi N; Izumi T; Umemura M; Ito J; Nakai M; Suda G; Ogawa K; Chuma M; Meguro T; Nakamura M; Nagasaka A; Horimoto H; Yamamoto Y; Sakamoto N
Drugs R D; 2017 Sep; 17(3):381-388. PubMed ID: 28573606
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.
Hagihara A; Ikeda M; Ueno H; Morizane C; Kondo S; Nakachi K; Mitsunaga S; Shimizu S; Kojima Y; Suzuki E; Katayama K; Imanaka K; Tamai C; Inaba Y; Sato Y; Kato M; Okusaka T
Cancer Sci; 2014 Mar; 105(3):354-8. PubMed ID: 24438504
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Naito S; Sakai H; Hashine K; Tomita Y; Shinohara N; Fujisawa M; Eto M; Ozono S; Akaza H
Ann Oncol; 2015 Sep; 26(9):1871-1876. PubMed ID: 26117830
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
[TBL] [Abstract][Full Text] [Related]
15. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma.
Furuse J; Okusaka T; Kaneko S; Kudo M; Nakachi K; Ueno H; Yamashita T; Ueshima K
Cancer Sci; 2010 Dec; 101(12):2606-11. PubMed ID: 20946314
[TBL] [Abstract][Full Text] [Related]
17. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Chan SL; Lin CC; Chiorean EG; Holcombe RF; Mulcahy MF; Carter WD; Patel K; Wilson WR; Melink TJ; Gutheil JC; Tsao CJ
Cancer Chemother Pharmacol; 2011 Aug; 68(2):539-45. PubMed ID: 21594722
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Brade AM; Ng S; Brierley J; Kim J; Dinniwell R; Ringash J; Wong RR; Cho C; Knox J; Dawson LA
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):580-7. PubMed ID: 26867886
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yokosuka AO
Invest New Drugs; 2014 Aug; 32(4):762-8. PubMed ID: 24737402
[TBL] [Abstract][Full Text] [Related]
20. Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.
Duffy AG; Ma C; Ulahannan SV; Rahma OE; Makarova-Rusher O; Cao L; Yu Y; Kleiner DE; Trepel J; Lee MJ; Tomita Y; Steinberg SM; Heller T; Turkbey B; Choyke PL; Peer CJ; Figg WD; Wood BJ; Greten TF
Clin Cancer Res; 2017 Aug; 23(16):4633-4641. PubMed ID: 28465443
[No Abstract] [Full Text] [Related]
[Next] [New Search]
